Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia

James H. O'Keefe, William Harris, Judy Nelson, Sheryl L. Windsor

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

This study was designed to evaluate the therapeutic effectiveness of 3 different pharmacologic lipid-lowering regimens in the treatment of patients with clustered lipid risk factors. Sixty-five patients with low high-density lipoprotein (HDL) levels and hypertriglyceridemia were randomized to 1 of 3 treatment arms: pravastatin/ niacin, pravastatin/magnesium, or pravastatin/placebo. After 18 weeks, patients in the pravastafin/niacin group had a -41% change in the total cholesterol/HDL ratio compared with -13% in the pravastatin/magnesium arm and -16% in the pravastatin/placebo group. The HDL2 and HDL3 subfractions, as well as the apolipoprotein A-l levels, were increased significantly only in the pravastatin/niacin arm. The levels of small dense low-density lipoprotein (LDL) cholesterol (LDL3) were decreased to a greater extent in the pravastatin/niacin arm (-43%) than in either the pravastatin/magnesium (-13%) or the pravastatin/placebo (-20%) arm. Only the pravastatin/ niacin regimen significantly diminished postprandial lipemia (-32% change in the remnant particle triglyceride concentration and decreased very-low-density lipoprotein remnant levels). Thus, in this group of patients with clustered risk factors, the combination of pravastatin and niacin resulted in significant improvements in HDL and triglyceride levels, total cholesterol to HDL ratio, small dense LDL levels, and postprandial lipemia. Pravastatin alone or in combination with magnesium resulted in less significant changes that were largely limited to LDL cholesterol reduction.

Original languageEnglish (US)
Pages (from-to)480-484
Number of pages5
JournalThe American Journal of Cardiology
Volume76
Issue number7
DOIs
StatePublished - Sep 1 1995
Externally publishedYes

Fingerprint

Pravastatin
Niacin
Hyperlipidemias
Magnesium
Lipids
Placebos
HDL Lipoproteins
LDL Lipoproteins
LDL Cholesterol
HDL Cholesterol
Apolipoproteins A
VLDL Lipoproteins
Hypertriglyceridemia
Triglycerides
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. / O'Keefe, James H.; Harris, William; Nelson, Judy; Windsor, Sheryl L.

In: The American Journal of Cardiology, Vol. 76, No. 7, 01.09.1995, p. 480-484.

Research output: Contribution to journalArticle

O'Keefe, James H. ; Harris, William ; Nelson, Judy ; Windsor, Sheryl L. / Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. In: The American Journal of Cardiology. 1995 ; Vol. 76, No. 7. pp. 480-484.
@article{58e32114d4714ed599ed5bd088ff0629,
title = "Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia",
abstract = "This study was designed to evaluate the therapeutic effectiveness of 3 different pharmacologic lipid-lowering regimens in the treatment of patients with clustered lipid risk factors. Sixty-five patients with low high-density lipoprotein (HDL) levels and hypertriglyceridemia were randomized to 1 of 3 treatment arms: pravastatin/ niacin, pravastatin/magnesium, or pravastatin/placebo. After 18 weeks, patients in the pravastafin/niacin group had a -41{\%} change in the total cholesterol/HDL ratio compared with -13{\%} in the pravastatin/magnesium arm and -16{\%} in the pravastatin/placebo group. The HDL2 and HDL3 subfractions, as well as the apolipoprotein A-l levels, were increased significantly only in the pravastatin/niacin arm. The levels of small dense low-density lipoprotein (LDL) cholesterol (LDL3) were decreased to a greater extent in the pravastatin/niacin arm (-43{\%}) than in either the pravastatin/magnesium (-13{\%}) or the pravastatin/placebo (-20{\%}) arm. Only the pravastatin/ niacin regimen significantly diminished postprandial lipemia (-32{\%} change in the remnant particle triglyceride concentration and decreased very-low-density lipoprotein remnant levels). Thus, in this group of patients with clustered risk factors, the combination of pravastatin and niacin resulted in significant improvements in HDL and triglyceride levels, total cholesterol to HDL ratio, small dense LDL levels, and postprandial lipemia. Pravastatin alone or in combination with magnesium resulted in less significant changes that were largely limited to LDL cholesterol reduction.",
author = "O'Keefe, {James H.} and William Harris and Judy Nelson and Windsor, {Sheryl L.}",
year = "1995",
month = "9",
day = "1",
doi = "10.1016/S0002-9149(99)80134-9",
language = "English (US)",
volume = "76",
pages = "480--484",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia

AU - O'Keefe, James H.

AU - Harris, William

AU - Nelson, Judy

AU - Windsor, Sheryl L.

PY - 1995/9/1

Y1 - 1995/9/1

N2 - This study was designed to evaluate the therapeutic effectiveness of 3 different pharmacologic lipid-lowering regimens in the treatment of patients with clustered lipid risk factors. Sixty-five patients with low high-density lipoprotein (HDL) levels and hypertriglyceridemia were randomized to 1 of 3 treatment arms: pravastatin/ niacin, pravastatin/magnesium, or pravastatin/placebo. After 18 weeks, patients in the pravastafin/niacin group had a -41% change in the total cholesterol/HDL ratio compared with -13% in the pravastatin/magnesium arm and -16% in the pravastatin/placebo group. The HDL2 and HDL3 subfractions, as well as the apolipoprotein A-l levels, were increased significantly only in the pravastatin/niacin arm. The levels of small dense low-density lipoprotein (LDL) cholesterol (LDL3) were decreased to a greater extent in the pravastatin/niacin arm (-43%) than in either the pravastatin/magnesium (-13%) or the pravastatin/placebo (-20%) arm. Only the pravastatin/ niacin regimen significantly diminished postprandial lipemia (-32% change in the remnant particle triglyceride concentration and decreased very-low-density lipoprotein remnant levels). Thus, in this group of patients with clustered risk factors, the combination of pravastatin and niacin resulted in significant improvements in HDL and triglyceride levels, total cholesterol to HDL ratio, small dense LDL levels, and postprandial lipemia. Pravastatin alone or in combination with magnesium resulted in less significant changes that were largely limited to LDL cholesterol reduction.

AB - This study was designed to evaluate the therapeutic effectiveness of 3 different pharmacologic lipid-lowering regimens in the treatment of patients with clustered lipid risk factors. Sixty-five patients with low high-density lipoprotein (HDL) levels and hypertriglyceridemia were randomized to 1 of 3 treatment arms: pravastatin/ niacin, pravastatin/magnesium, or pravastatin/placebo. After 18 weeks, patients in the pravastafin/niacin group had a -41% change in the total cholesterol/HDL ratio compared with -13% in the pravastatin/magnesium arm and -16% in the pravastatin/placebo group. The HDL2 and HDL3 subfractions, as well as the apolipoprotein A-l levels, were increased significantly only in the pravastatin/niacin arm. The levels of small dense low-density lipoprotein (LDL) cholesterol (LDL3) were decreased to a greater extent in the pravastatin/niacin arm (-43%) than in either the pravastatin/magnesium (-13%) or the pravastatin/placebo (-20%) arm. Only the pravastatin/ niacin regimen significantly diminished postprandial lipemia (-32% change in the remnant particle triglyceride concentration and decreased very-low-density lipoprotein remnant levels). Thus, in this group of patients with clustered risk factors, the combination of pravastatin and niacin resulted in significant improvements in HDL and triglyceride levels, total cholesterol to HDL ratio, small dense LDL levels, and postprandial lipemia. Pravastatin alone or in combination with magnesium resulted in less significant changes that were largely limited to LDL cholesterol reduction.

UR - http://www.scopus.com/inward/record.url?scp=0029066170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029066170&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)80134-9

DO - 10.1016/S0002-9149(99)80134-9

M3 - Article

C2 - 7653448

AN - SCOPUS:0029066170

VL - 76

SP - 480

EP - 484

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -